ELAINE J. HERON, PH.D.

Corporate Board Profile

Tech Score: 0/100

← Back to All Directors

BIOMARIN PHARMACEUTICAL INC

Filing Date Source Excerpt
2016-04-25 Elaine J. Heron, Ph.D., joined our Board in July 2002 and serves as the Chair of the CGN Committee. ... The CGN Committee is composed of four directors, each of whom is “independent” under the listing standards of NASDAQ. The members of the CGN Committee are Dr. Heron (Chair), Mr. Lapalme, Mr. Pyott and Dr. Slamon. ... Director Compensation in 2015 table shows Elaine J. Heron's total compensation as $420,695.
2017-04-25 Elaine J. Heron, Ph.D., 69, joined our Board in July 2002. Chair of the Corporate Governance and Nominating Committee. Serves on Audit Committee. 2016 Independent Director Compensation: $387,464.
2018-04-24 Elaine J. Heron, Ph.D., 70, July 2002, Director, Amplyx Pharmaceuticals, Inc.
2019-04-23 Elaine J. Heron, Ph.D., 71, July 2002, Director, Amplyx Pharmaceuticals, Inc.; Director, Vala Sciences Inc.; Director, Palvella Therapeutics; Director, Dropworks, Inc.
2020-04-14 Elaine J. Heron, Ph.D., joined our Board in July 2002 and serves as the Chair of the Corporate Governance and Nominating Committee. Dr. Heron served as Chair and Chief Executive Officer of Amplyx Pharmaceuticals, Inc., a private drug development company, from February 2009 until October 2015.
2021-04-13 Elaine J. Heron, Ph.D., joined our Board in July 2002 and serves as the Chair of the Corporate Governance and Nominating Committee. Dr. Heron served as Chair and Chief Executive Officer of Amplyx Pharmaceuticals, Inc., a private drug development company, from February 2009 until October 2015, and she continues to serve as a member of that company’s board. The Audit Committee is currently composed of four directors: Mr. Hombach (Chair), Dr. Heron, Dr. Ho and Dr. Lawlis. The CGN Committee is currently composed of four directors, each of whom is “independent” under the listing standards of Nasdaq. The members of the CGN Committee are Dr. Heron (Chair), Ms. Anderson, Dr. Dere and Dr. Pyott. The Science and Technology Committee is currently composed of six directors: Dr. Dere (Chair), Mr. Grey, Dr. Heron, Dr. Ho, Dr. Lawlis and Dr. Slamon. 2020 INDEPENDENT DIRECTOR COMPENSATION: Elaine J. Heron, Ph.D. Fees Earned ($) 107,250 Stock Awards ($) 458,810 Total ($) 566,060.
2022-04-12 Elaine J. Heron, Ph.D., 74, Director Since July 2002, Director, Palvella Therapeutics; Director, Visgenx, Inc.; Director, Watershed Medical, Inc. Chair of the Corporate Governance and Nominating Committee. 2021 INDEPENDENT DIRECTOR COMPENSATION: Fees Earned or Paid in Cash $107,250, Stock Awards $397,312, Total $504,562.
2023-04-11 Elaine J. Heron, Ph.D. joined our Board in July 2002. From February 2009 to October 2015, Dr. Heron served as Chair and CEO of Amplyx Pharmaceuticals, Inc., a private drug development company acquired by Pfizer, Inc. in April 2021. Dr. Heron currently serves on the boards of Vaxart, Inc., a public clinical-stage biotechnology company, Visgenx, Inc., a private preclinical-stage therapeutics company, and Watershed Medical, Inc., a private early-stage therapeutics company. Dr. Heron is also an advisor to Kyto Technology and Life Science, Inc. and Cairn Biosciences, Inc. From July 2001 to October 2008, Dr. Heron was Chair and CEO of Labcyte Inc., a private biotechnology company. Before joining Labcyte Inc., Dr. Heron spent six years in positions of increasing responsibility at the Applied Biosystems Group of Applera Corporation, a biotechnology company, including the position of General Manager and Vice President of Sales and Marketing. Dr. Heron earned a B.S. in chemistry with highest distinction and a Ph.D. in analytical biochemistry from Purdue University and an M.B.A. from Pepperdine University.
2024-04-09 Elaine J. Heron, Ph.D. joined our Board in July 2002. ... 2023 Independent Director Compensation ... Elaine J. Heron, Ph.D. 101,000 Fees Earned or Paid in Cash, 385,438 Stock Awards, 486,438 Total.

Vaxart, Inc.

Filing Date Source Excerpt
2023-04-28 Elaine J. Heron, Ph.D. has served as a member of our board of directors since August 2022. Dr. Heron has served on the board of directors of BioMarin Pharmaceutical Inc. since July 2002. From February 2009 to October 2015, Dr. Heron served as Chair and CEO of Amplyx Pharmaceuticals, Inc., a private drug development company acquired by Pfizer, Inc. in April 2021. She currently serves on the boards of Visgenx, Inc., a private early-stage therapeutics company, and Watershed Medical, Inc., a private early-stage therapeutics company. She is also an advisor to Kyto Technology and Life Science, Inc. From July 2001 to October 2008, Dr. Heron was Chair and CEO of Labcyte Inc., a private biotechnology company. Before joining Labcyte Inc., she spent six years in positions of increasing responsibility at the Applied Biosystems Group of Applera Corporation, including General Manager and Vice President of Sales and Marketing. Dr. Heron earned a B.S. in chemistry with highest distinction and a Ph.D. in analytical biochemistry from Purdue University and an M.B.A. from Pepperdine University. The following table provides director compensation information for each of the non-employee directors of the board of directors who served between January 1, 2022 and December 31, 2022: Elaine J. Heron, Ph.D. Fees Earned or Paid in Cash: $18,404, Stock Awards: $49,560, Option Awards: $265,371, Total: $333,335.
2024-04-29 Elaine J. Heron, Ph.D. has served as a member of our board of directors since August 2022.

Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22